Maternal Choline Supplementation Protects Against Age-associated Cholinergic and GABAergic Basal Forebrain Neuron Degeneration in the Ts65Dn Mouse Model of Down Syndrome and Alzheimer's Disease

Overview

Journal Neurobiol Dis

Specialty Neurology

Date 2023 Oct 27

PMID 37890559

Authors

Megan K Gautier

Christy M Kelley

Sang Han Lee

Melissa J Alldred

John McDaid

Elliott J Mufson

Grace E Stutzmann

Stephen D Ginsberg

Affiliations

Soon will be listed here.

Abstract

Down syndrome (DS) is a genetic disorder caused by triplication of human chromosome 21. In addition to intellectual disability, DS is defined by a premature aging phenotype and Alzheimer's disease (AD) neuropathology, including septohippocampal circuit vulnerability and degeneration of basal forebrain cholinergic neurons (BFCNs). The Ts65Dn mouse model recapitulates key aspects of DS/AD pathology, namely age-associated atrophy of BFCNs and cognitive decline in septohippocampal-dependent behavioral tasks. We investigated whether maternal choline supplementation (MCS), a well-tolerated treatment modality, protects vulnerable BFCNs from age- and genotype-associated degeneration in trisomic offspring. We also examined the effect of trisomy, and MCS, on GABAergic basal forebrain parvalbumin neurons (BFPNs), an unexplored neuronal population in this DS model. Unbiased stereological analyses of choline acetyltransferase (ChAT)-immunoreactive BFCNs and parvalbumin-immunoreactive BFPNs were conducted using confocal z-stacks of the medial septal nucleus and the vertical limb of the diagonal band (MSN/VDB) in Ts65Dn mice and disomic (2N) littermates at 3-4 and 10-12 months of age. MCS trisomic offspring displayed significant increases in ChAT-immunoreactive neuron number and density compared to unsupplemented counterparts, as well as increases in the area of the MSN/VDB occupied by ChAT-immunoreactive neuropil. MCS also rescued BFPN number and density in Ts65Dn offspring, a novel rescue of a non-cholinergic cell population. Furthermore, MCS prevented age-associated loss of BFCNs and MSN/VDB regional area in 2N offspring, indicating genotype-independent neuroprotective benefits. These findings demonstrate MCS provides neuroprotection of vulnerable BFCNs and non-cholinergic septohippocampal BFPNs, indicating this modality has translational value as an early life therapy for DS, as well as extending benefits to the aging population at large.

Citing Articles

Profiling hippocampal neuronal populations reveals unique gene expression mosaics reflective of connectivity-based degeneration in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.

Alldred M, Ibrahim K, Pidikiti H, Lee S, Heguy A, Chiosis G Front Mol Neurosci. 2025; 18:1546375.

PMID: 40078964 PMC: 11897496. DOI: 10.3389/fnmol.2025.1546375.

Assessing the Benefit of Dietary Choline Supplementation Throughout Adulthood in the Ts65Dn Mouse Model of Down Syndrome.

Tallino S, Etebari R, McDonough I, Leon H, Sepulveda I, Winslow W Nutrients. 2024; 16(23).

PMID: 39683562 PMC: 11644426. DOI: 10.3390/nu16234167.

Maternal choline supplementation rescues early endosome pathology in basal forebrain cholinergic neurons in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.

Gautier M, Kelley C, Lee S, Mufson E, Ginsberg S Neurobiol Aging. 2024; 144:30-42.

PMID: 39265450 PMC: 11490376. DOI: 10.1016/j.neurobiolaging.2024.09.002.

Hippocampal CA1 Pyramidal Neurons Display Sublayer and Circuitry Dependent Degenerative Expression Profiles in Aged Female Down Syndrome Mice.

Alldred M, Pidikiti H, Ibrahim K, Lee S, Heguy A, Hoffman G J Alzheimers Dis. 2024; 100(s1):S341-S362.

PMID: 39031371 PMC: 11497160. DOI: 10.3233/JAD-240622.

Choline supplementation in early life improves and low levels of choline can impair outcomes in a mouse model of Alzheimer's disease.

Chartampila E, Elayouby K, Leary P, LaFrancois J, Alcantara-Gonzalez D, Jain S Elife. 2024; 12.

PMID: 38904658 PMC: 11192536. DOI: 10.7554/eLife.89889.

References

Thomas J, Abou E, Dominguez H . Prenatal choline supplementation mitigates the adverse effects of prenatal alcohol exposure on development in rats. Neurotoxicol Teratol. 2009; 31(5):303-11. PMC: 2952280. DOI: 10.1016/j.ntt.2009.07.002. View

Alldred M, Chao H, Lee S, Beilin J, Powers B, Petkova E . Long-term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease. FASEB J. 2019; 33(9):9871-9884. PMC: 6704451. DOI: 10.1096/fj.201802669RR. View

Yang Y, Liu Z, Cermak J, Tandon P, Sarkisian M, Stafstrom C . Protective effects of prenatal choline supplementation on seizure-induced memory impairment. J Neurosci. 2000; 20(22):RC109. PMC: 6773159. View

Davisson M, Schmidt C, Akeson E . Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog Clin Biol Res. 1990; 360:263-80. View

Reeves R, Irving N, Moran T, WOHN A, Kitt C, Sisodia S . A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet. 1995; 11(2):177-84. DOI: 10.1038/ng1095-177. View

Kahlem P, Sultan M, Herwig R, Steinfath M, Balzereit D, Eppens B . Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of down syndrome. Genome Res. 2004; 14(7):1258-67. PMC: 442140. DOI: 10.1101/gr.1951304. View

Cataldo A, Peterhoff C, Troncoso J, Gomez-Isla T, Hyman B, Nixon R . Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol. 2000; 157(1):277-86. PMC: 1850219. DOI: 10.1016/s0002-9440(10)64538-5. View

Costa A . The glutamatergic hypothesis for Down syndrome: the potential use of N-methyl-D-aspartate receptor antagonists to enhance cognition and decelerate neurodegeneration. CNS Neurol Disord Drug Targets. 2013; 13(1):16-25. DOI: 10.2174/18715273113126660183. View

McCann J, Hudes M, Ames B . An overview of evidence for a causal relationship between dietary availability of choline during development and cognitive function in offspring. Neurosci Biobehav Rev. 2006; 30(5):696-712. DOI: 10.1016/j.neubiorev.2005.12.003. View

10.

Ballinger E, Ananth M, Talmage D, Role L . Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. Neuron. 2016; 91(6):1199-1218. PMC: 5036520. DOI: 10.1016/j.neuron.2016.09.006. View

11.

Escorihuela R, Fernandez-Teruel A, Vallina I, Baamonde C, Lumbreras M, Dierssen M . A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci Lett. 1995; 199(2):143-6. DOI: 10.1016/0304-3940(95)12052-6. View

12.

Costa A, Scott-McKean J . Prospects for improving brain function in individuals with Down syndrome. CNS Drugs. 2013; 27(9):679-702. DOI: 10.1007/s40263-013-0089-3. View

13.

Kaur G, Pawlik M, Gandy S, Ehrlich M, Smiley J, Levy E . Lysosomal dysfunction in the brain of a mouse model with intraneuronal accumulation of carboxyl terminal fragments of the amyloid precursor protein. Mol Psychiatry. 2016; 22(7):981-989. PMC: 5405008. DOI: 10.1038/mp.2016.189. View

14.

Nag N, Berger-Sweeney J . Postnatal dietary choline supplementation alters behavior in a mouse model of Rett syndrome. Neurobiol Dis. 2007; 26(2):473-80. DOI: 10.1016/j.nbd.2007.02.003. View

15.

Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K . Down syndrome and Alzheimer's disease: Common pathways, common goals. Alzheimers Dement. 2014; 11(6):700-9. PMC: 4817997. DOI: 10.1016/j.jalz.2014.10.007. View

16.

Jiang Y, Mullaney K, Peterhoff C, Che S, Schmidt S, Boyer-Boiteau A . Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci U S A. 2010; 107(4):1630-5. PMC: 2824382. DOI: 10.1073/pnas.0908953107. View

17.

Ikonomovic M, Mufson E, Wuu J, Cochran E, Bennett D, DeKosky S . Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology. J Alzheimers Dis. 2003; 5(1):39-48. DOI: 10.3233/jad-2003-5106. View

18.

Contestabile A, Fila T, Bartesaghi R, Contestabile A, Ciani E . Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down's syndrome and related neurodegenerative diseases. J Neurochem. 2006; 97(2):515-26. DOI: 10.1111/j.1471-4159.2006.03769.x. View

19.

Schliebs R, Arendt T . The cholinergic system in aging and neuronal degeneration. Behav Brain Res. 2010; 221(2):555-63. DOI: 10.1016/j.bbr.2010.11.058. View

20.

Driscoll L, Carroll J, Moon J, Crnic L, Levitsky D, Strupp B . Impaired sustained attention and error-induced stereotypy in the aged Ts65Dn mouse: a mouse model of Down syndrome and Alzheimer's disease. Behav Neurosci. 2004; 118(6):1196-205. DOI: 10.1037/0735-7044.118.6.1196. View